Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Study of Efficacy and Safety of Novel Targeted Drugs Combined With R-ICE Regimen in the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma

Next Previous
Search
Trial Profile

Clinical Study of Efficacy and Safety of Novel Targeted Drugs Combined With R-ICE Regimen in the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Decitabine (Primary) ; Etoposide (Primary) ; Ifosfamide (Primary) ; Lenalidomide (Primary) ; Pomalidomide (Primary) ; Rituximab (Primary) ; Tofacitinib (Primary) ; Tucidinostat (Primary) ; Zanubrutinib (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms R-ICE+X

    • Most Recent Events

    • 26 Jul 2023 New trial record
    • 15 Jun 2023 Results (data cut off n=51) presented at the 28th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top